© 2022 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#EASL 2012
Click Here for More Conferences
Click Here for EASL.eu
An Introduction to Hepatitis

Interferon-Free BMS Combo Yields 77% Cure Rate in Geno 1 Hep C

A 24-week, interferon-free regimen pairing two drugs from Bristol-Myers Squibb--60 milligrams (mg) of daclatasvir, a once-daily NS5a...

PILOT Study: Three-Month Interferon-Free Regimen Cures 9 of 11 Geno 1, IL-28B CC Hep C Patients

A 12-week, interferon-free combination of two experimental, once-daily drugs cured nine of 11 (82 percent) first-time treatment takers

COPILOT Study: Second Three-Month Inteferon-Free Abbott Regimen Versus Geno 1 Hep C

A 12-week regimen of ribavirin plus two experimental drugs kept HCV levels undetectable for 12 weeks after completing treatment in over 90%

MUST read

Hepatitis C: The Basics
Hepatitis B: The Basics
Hepatitis A: The Basics

Efficacy of 12-Week GS-7977/Ribavirin Combo for Hep C Geno 1 Varies by IL-28B Status

Early follow-up data continues to show promise as a cornerstone of interferon-free treatment

Novel Lambda Peg-Interferon Has Safety Edge Over Approved Peg-Interferon

A novel version of interferon, pegylated interferon lambda-1a (peg-IFN-lambda), combined with ribavirin cured up to three-quarters of...

Interferon-Free Gilead and BMS Combo Shows High Cure Rate Potential

All-oral treatment kept undetectable for four weeks after treatment in 100% of people genotype 1 infection and 91% of people with 2 or 3

Hot topics

Forums: Support and discussion
Blogs: The community speaks

90% Geno 1 Patients Nearing Cure in 7977/Interferon Study

Ninety percent of people with genotype 1 hepatitis C virus (HCV) starting therapy for the first time show a clear sign of being cured

TMC435 Boosts Cure Rates in Previously Treated Geno 1 HCV Patients

Up to 80 percent of people with genotype 1 hepatitis C virus (HCV) who didn’t respond successfully to earlier therapy were cured

Victrelis Shows Effectiveness for Prior Treatment Null Responders

Additional data from a Merck-sponsored clinical trial help clarify the efficacy of Victrelis combined with interferon and ribavirin
Advertisement
Science News
Newsfeed
Features
Ask Hep

Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.